title: Alterations in coagulation and fibrinolysis after surgery for aortic aneurysm.
abstract: We investigated the alterations in the coagulation and fibrinolysis systems after aortic aneurysm surgery under cardiopulmonary bypass (CPB) while using newly developed "molecular markers". Fibrinogen and antithrombin III (AT-III) decreased after surgery but returned to normal values within three days. The thrombin-antithrombin III complex (TAT) and plasmin-alpha-2-plasmin inhibitor complex (PIC) both showed increased values even preoperatively, which indicated that coagulation and fibrinolysis were activated in some patients with an aortic aneurysm. Both markers maintained a high level for at least 14 days after surgery. The fibrin degradation product (FDP) also showed an increased value before and after surgery. These results apparently showed that coagulation/fibrinolysis had already been activated in some patients and maintained such a state for at least 14 days after surgery. The relation of activated system and postoperative organ dysfunction as well as the means to suppress such activation are also discussed.
authors.affiliation: Department of Cardiovascular Surgery, Hokkaido University School of Medicine, Sapporo, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Oba
authors.forename: N
authors.initials: N
authors.lastname: Shiiya
authors.forename: Y
authors.initials: Y
authors.lastname: Matsui
authors.forename: T
authors.initials: T
authors.lastname: Goda
authors.forename: M
authors.initials: M
authors.lastname: Sakuma
authors.forename: K
authors.initials: K
authors.lastname: Yasuda
mesh_terms: D000368:Aged; D000784:Aortic Dissection / Q000097:blood / Q000601:surgery*; D000933:Antifibrinolytic Agents; D000990:Antithrombin III / Q000378:metabolism; D017544:Aortic Aneurysm, Abdominal / Q000097:blood / Q000601:surgery*; D017545:Aortic Aneurysm, Thoracic / Q000097:blood / Q000601:surgery*; D001780:Blood Coagulation Tests; D002315:Cardiopulmonary Bypass; D004211:Disseminated Intravascular Coagulation / Q000097:blood*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000378:metabolism; D011183:Postoperative Complications / Q000097:blood*; D012016:Reference Values; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood*; D000979:alpha-2-Antiplasmin / Q000378:metabolism; D000511:alpha-Macroglobulins
chemical_list: D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; D000511:alpha-Macroglobulins; C024668:plasmin-alpha(2)-macroglobulin complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D005340:Fibrinogen; D010447:Peptide Hydrolases; D005341:Fibrinolysin